TY - JOUR
T1 - Enteral docosahexaenoic acid reduces analgesic administration in neonates undergoing cardiovascular surgery
AU - Bernabe-Garcia, Mariela
AU - López-Alarcon, Mardia
AU - Salgado-Sosa, Alfredo
AU - Villegas-Silva, Raul
AU - Maldonado-Hernandez, Jorge
AU - Rodríguez-Cruz, Maricela
AU - Rivas-Ruiz, Rodolfo
AU - Chavez-Sanchez, Luis
AU - Blanco-Favela, Francisco A.
AU - Mancilla-Ramirez, Javier
AU - Gordillo-Alvarez, Virginia
AU - Madrigal-Muñiz, Olivia
N1 - Publisher Copyright:
© 2016 S. Karger AG, Basel.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background: Neonates undergoing surgery require analgesic medication to ameliorate acute pain. These medications produce negative side effects. Docosahexaenoic acid (DHA) has an antinociceptive effect in animals, but this has not been evaluated in human neonates. We evaluated the DHA effect on cumulative dose and duration of analgesics administered to neonates undergoing cardiovascular surgery. Methods: A secondary analysis was performed with data from a clinical trial, in which enteral DHA was administered perioperatively compared with sunflower oil (SO). Present study assessed the antinociceptive effect of DHA by measuring the cumulative dose and duration of analgesics administered during postoperative stay in a neonatal intensive care unit. Multivariate linear regression models were performed. Results: Seventeen neonates received DHA and 18 received SO in the control group. Compared with the control group, the DHA group received lower cumulative dose (14.6 ± 2.2 vs. 25.2 ± 4.8 μg/kg, p = 0.029) and shorter duration of buprenorphine (2 days (1-8) vs. 4.5 days (1-12); p = 0.053). After adjusting for confounders, the DHA group received significantly lesser buprenorphine (β = -27 μg/kg, p = 0.028; R2 model = 0.90) for shorter duration (β = -9 days, p = 0.003; R2 model = 0.94). No differences in fentanyl or ketorolac were detected. Conclusions: Buprenorphine administration was reduced in neonates who received DHA, suggesting that DHA likely has analgesic effects.
AB - Background: Neonates undergoing surgery require analgesic medication to ameliorate acute pain. These medications produce negative side effects. Docosahexaenoic acid (DHA) has an antinociceptive effect in animals, but this has not been evaluated in human neonates. We evaluated the DHA effect on cumulative dose and duration of analgesics administered to neonates undergoing cardiovascular surgery. Methods: A secondary analysis was performed with data from a clinical trial, in which enteral DHA was administered perioperatively compared with sunflower oil (SO). Present study assessed the antinociceptive effect of DHA by measuring the cumulative dose and duration of analgesics administered during postoperative stay in a neonatal intensive care unit. Multivariate linear regression models were performed. Results: Seventeen neonates received DHA and 18 received SO in the control group. Compared with the control group, the DHA group received lower cumulative dose (14.6 ± 2.2 vs. 25.2 ± 4.8 μg/kg, p = 0.029) and shorter duration of buprenorphine (2 days (1-8) vs. 4.5 days (1-12); p = 0.053). After adjusting for confounders, the DHA group received significantly lesser buprenorphine (β = -27 μg/kg, p = 0.028; R2 model = 0.90) for shorter duration (β = -9 days, p = 0.003; R2 model = 0.94). No differences in fentanyl or ketorolac were detected. Conclusions: Buprenorphine administration was reduced in neonates who received DHA, suggesting that DHA likely has analgesic effects.
KW - Analgesic
KW - Buprenorphine
KW - Docosahexaenoic acid
KW - N-3 fatty acids
KW - Neonate
KW - Pain
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84994134115&partnerID=8YFLogxK
U2 - 10.1159/000452227
DO - 10.1159/000452227
M3 - Artículo
C2 - 27806350
SN - 0250-6807
VL - 69
SP - 150
EP - 160
JO - Annals of Nutrition and Metabolism
JF - Annals of Nutrition and Metabolism
IS - 2
ER -